ESSEX BIO-TECHNOLOGY LIMITED

(Stock Code : 1061)

2022 Interim Results AT A GLANCE

Financial Highlights

Turnover (HK$ Million)

656

Net Profit (HK$ Million)

139

Cash & Cash Equivalents (HK$ Million)

641

Dividend Per Ordinary Share (HK$)

0.04

Gearing Ratio

0.38

Return on Equity

8.0%

Net Profit Margin

21.2%

Total Expenditures Incurred in R&D (HK$ Million) **& % of the turnover**

	HI 2021	HI 2022
Total Expenditures Incurred in R&D (HK$ Million)	86	197
% of the turnover	12%	30%

130%

Segment Analysis

Ophthalmology

Beifushu series 适丽康®

Unit-dose eye drops series

Segment Revenue (HK$ Million)

269

Segment Profit (HK$ Million)

87

Surgical (wound care and healing)

Beifuji series

Beifuxin series

Dental series

Segment Revenue (HK$ Million)

386

Segment Profit (HK$ Million)

106

41.1% / 58.9%

Total Profit, Combined (HK$ Million)

193

Profit Margin

29.4%

Strategy Execution Highlights

R&D 1H 2022 Snapshot

- 15 R&D programmes in the pre-clinical to clinical stage, out of which 3 ophthalmology programmes are in clinical stage;
- 64 patent certificates or authorisation letters: 47 invention patents, 12 utility model patents and 5 design patents.

Clinical Trial Updates for EB12-20145P

In 2020, the Group started co-development on a recombinant anti-VEGF humanised monoclonal antibody (EB12-20145P) for the treatment of wet-AMD, with Shanghai Henlius Biotech, Inc. During the period, EB12-20145P has since been approved to commence phase 3 clinical trials in various territories including (Australia, China, European Union, Singapore and the United States of America.), with the first patients dosed in Australia, China and the European Union.

Successful Acquisition of 适丽康® (Iodized Lecithin Capsules)

In 1H 2022 The Group has completed the acquisition of intellectual property rights relating to technologies, processes of product research and development, production as well as right of Marketing Authorisation Holder of 适丽康® (Iodized Lecithin Capsules). Since the acquisition, 适丽康® is regarded a core product in the Group's product portfolio.

Strong Market Access

- **Offline channel**

Regional Sales Offices **43**

Representatives **1,255**

Pharmaceutical stores **2,120**

Hospitals **10,710**

- **Online channel**

Adding Telemedicine ("TM") and 2 online platforms to compliment offline channels.

Registered Doctors **15,000+**

Registered Patients **1,200,000+**

As at 30 June 2022

In 2021, it was designated as an online prescription drug platform by the Indonesian government. Indonesia has a market potential of more than **270** million users.

Corporate Honours

Essex was included in **"Forbes Asia's 200 Best Under A Billion 2022"** - for the Group's outstanding long-term sustainable development across a variety of metrics.

- Chairman of Essex Bio-Technology, Patrick Ngiam, awarded as one of **10 Most Trustable Entrepreneurs from Pharmaceutical Industry** for 2022 by APAC Entrepreneur Magazine
- Zhuhai Essex Bio-Pharmaceutical Company Limited was awarded as one of the **2021 top 10 pharmaceutical and health manufacturing companies in Zhuhai**.
- Zhuhai Essex was also awarded as one of the **2021 top 100 chemical pharmaceutical companies in the PRC**.
- The Group's Beifushu has been awarded as one of the **Chinese reputable medicine brands** in 4 consecutive years.
- Nominated by Hong Kong Investor Relations Association (HKIRA) as **Best IR Company of 2022**.

Forward-Looking Statement

The sporadic emergence of COVID-19 in the PRC if persists will adversely influence our performance in the second half of 2022, despite the strong fundamentals and demands of our products in the market.

DISCLAIMER

The information is not presentation has been prepared by Essex Bio-Technology Limited ("Essex Bio" or the "Company") and is solely for your information and for use in presentations by Essex Bio in connection with the proposed transaction described herein. No accuracy or correctness of the information and that we have any liability for any representations (expressed or implied) regarding, or warranties of, the accuracy or completeness of the information, or any other written or oral information made available to any interested party or its advisers in the course of the evaluation of the Company.

This presentation may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to Essex Bio's business and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions, liquidity, prospects, growth, strategies and the industry in which Essex Bio operates. Forward looking statements in this Essex Bio's does not constitute an obligation to publicly release the result of any revisions to these forward looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forward looking statements, Essex Bio's actual results and developments may differ materially from the forward looking statements. Forward looking statements are subject to uncertainty and contingencies outside Essex Bio's control. Past performance is not a reliable indication of future performance.

This presentation is not an offer to any purchase or observation of the securities or financial products of the Company, and does not provide any financial advice. This presentation does not contain any terms and agreement or commitments is concerned in the Company.